Site Map | RYBREVANT® (amivantamab-vmjw) HCP

Mechanism of Action

Clinical Trial Results

First-Line EGFR+ mNSCLC

Second-Line EGFR+ mNSCLC

First-Line EGFR Exon20ins mNSCLC

RYBREVANT FASPRO™ vs RYBREVANT^® (PALOMA-3)

Dosage & Administration

RYBREVANT FASPRO™ + LAZCLUZE^®

RYBREVANT FASPRO™ + Chemotherapy

RYBREVANT^® + LAZCLUZE^®

RYBREVANT^® + Chemotherapy

Therapy Management

RYBREVANT FASPRO™ Proactive Therapy Management

RYBREVANT FASPRO™ Monitoring & Management

RYBREVANT^® Proactive Therapy Management

RYBREVANT^® Monitoring & Management

Support & Resources

HCP & Access Resources

Patient Support

Expert Perspectives

For APPs & Nurses